Abstract
The effects of growth hormone are mediated in part by stimulating the production of insulin-like growth factor-1. Insulin-like growth factor-1 has significant effects on cell proliferation and differentiation, it is a potent mitogen, and it is a powerful inhibitor of programmed cell death (apoptosis). Insulin-like growth factor-1 also has a well-established role in the transformation of normal cells to malignant cells. Case reports on a possible association between elevated growth hormone and cancer risk in a variety of patient groups have been published. Here, we describe clinical and laboratory findings for a patient with acromegaly who first developed thyroid cancer, and then, in the follow up period, probably due to poorly controlled insulin-like growth factor-1 levels, developed a large cell non-Hodgkin's lymphoma. A search revealed that a case with these peculiarities had not previously been reported.
MeSH terms
-
Acromegaly* / drug therapy
-
Acromegaly* / etiology
-
Adenoma / complications
-
Adenoma / metabolism*
-
Adenoma / surgery
-
Aged
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cabergoline
-
Cyclophosphamide / therapeutic use
-
Ergolines / therapeutic use
-
Human Growth Hormone / analogs & derivatives
-
Human Growth Hormone / metabolism
-
Human Growth Hormone / therapeutic use
-
Humans
-
Insulin-Like Growth Factor I / metabolism*
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / metabolism*
-
Male
-
Neoplasms, Multiple Primary*
-
Octreotide / therapeutic use
-
Prednisone / therapeutic use
-
Thyroid Neoplasms / complications
-
Thyroid Neoplasms / metabolism*
-
Thyroid Neoplasms / surgery
-
Thyroidectomy
-
Thyroxine / therapeutic use
-
Vincristine / therapeutic use
Substances
-
Antineoplastic Agents, Hormonal
-
Ergolines
-
Human Growth Hormone
-
Vincristine
-
Insulin-Like Growth Factor I
-
Cyclophosphamide
-
Cabergoline
-
pegvisomant
-
Thyroxine
-
Octreotide
-
Prednisone